Literature DB >> 10468029

Likelihood-based diagnostics for influential individuals in non-linear mixed effects model selection.

S Sadray1, E N Jonsson, M O Karlsson.   

Abstract

PURPOSE: Data from single individuals, or a small group of subjects may influence non-linear mixed effects model selection. Diagnostics routinely applied in model building may identify such individuals, but these methods are not specifically designed for that purpose and are, therefore, not optimal. We describe two likelihood-based diagnostics for identifying individuals that can influence the choice between two competing models.
METHODS: One method is based on a jackknife of the raw data on the individual level and refitting the model to each new data set. The second method is a calculation which utilises the contribution each individual make to the objective function values under each of the two models. The two methods were applied to model selection during analysis of a real data set.
RESULTS: The agreement between the methods was high. Individuals for whom there was a discrepancy between the methods tended to be those for which neither of the contending models described the data appropriately. Both methods identified individuals that influenced the model selection.
CONCLUSIONS: Two objective, specific and quantitative methods for identifying influential individuals in nonlinear mixed effects model selection have been presented. One of the methods doesn't require additional model fitting and is therefore particularly attractive.

Mesh:

Year:  1999        PMID: 10468029     DOI: 10.1023/a:1014857832337

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  7 in total

1.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

Authors:  E N Jonsson; M O Karlsson
Journal:  Comput Methods Programs Biomed       Date:  1999-01       Impact factor: 5.428

2.  Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects.

Authors:  J W Mandema; D Verotta; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

3.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

4.  A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam.

Authors:  P O Maitre; M Bührer; D Thomson; D R Stanski
Journal:  J Pharmacokinet Biopharm       Date:  1991-08

5.  Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients.

Authors:  M O Karlsson; E N Jonsson; C G Wiltse; J R Wade
Journal:  J Pharmacokinet Biopharm       Date:  1998-04

6.  Automated covariate model building within NONMEM.

Authors:  E N Jonsson; M O Karlsson
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

7.  Population pharmacokinetic modeling: the importance of informative graphics.

Authors:  E I Ette; T M Ludden
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

  7 in total
  6 in total

1.  Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis.

Authors:  Ulrika Wählby; Alison H Thomson; Peter A Milligan; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

2.  Semiparametric distributions with estimated shape parameters.

Authors:  Klas J F Petersson; Eva Hanze; Radojka M Savic; Mats O Karlsson
Journal:  Pharm Res       Date:  2009-07-01       Impact factor: 4.200

3.  Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke.

Authors:  Siv Jönsson; Yi-Fang Cheng; Charlotte Edenius; Kennedy R Lees; Tomas Odergren; Mats O Karlsson
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Assessment of the validity of a population pharmacokinetic model for epirubicin.

Authors:  Lorraine D Ralph; Marie Sandstrom; Chris Twelves; Nicola A Dobbs; Alison H Thomson
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

5.  Modeling subpopulations with the $MIXTURE subroutine in NONMEM: finding the individual probability of belonging to a subpopulation for the use in model analysis and improved decision making.

Authors:  Kristin C Carlsson; Radojka M Savić; Andrew C Hooker; Mats O Karlsson
Journal:  AAPS J       Date:  2009-03-10       Impact factor: 4.009

6.  Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression.

Authors:  Anthe S Zandvliet; Jan H M Schellens; William Copalu; Jos H Beijnen; Alwin D R Huitema
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-02-07       Impact factor: 2.745

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.